Lysosomal acid lipase regulatory update

FDA granted Orphan Drug designation to LAL to treat lysosomal acid lipase (LAL) recombinant enzyme deficiency diseases. The compound is partnered with BAYG's CropScience unit (Research Triangle Park, ...